Sierra MJG, Pacheco VC

Language: Spanish
References: 15
Page: 2-6
PDF size: 82.44 Kb.

ABSTRACT

Malnutrition is a frequent event in advanced stages of HIV infection. Within malnutrition pathogenesis associated with HIV three factors have been taken into account as being the main responsible ones: deficient nutritional contribution, faulty absorption and metabolic alteration. Poor oral ingestion caused by upper intestine, or by adverse effects from multiple medicines that the patients are given contributes to the deficient intestinal absorption. The wide range of intestine infectious pathologies causing downiness atrophy is responsible for deficient intestinal absorption. Alterations in basal metabolism have been described consisting of hypercatabolic states usually associated to added infectious processes which are responsible for the so called weakening syndrome. This, however, has not been a uniform finding in studies evaluating basal metabolism in a large number of patients. Within the pharmacological treatments employed against the weakening syndrome associated to HIV infection, it can be found appetite stimulants such as megestrol and dronabinol, anabolic agents such as growth hormone and anabolic steroids. Another approach is the use of cytosine modulators which are considered take part in weakening pathogenesis.

REFERENCES

1. Bunn PA Jr. Cancer and acquired immunodeficiency syndrome wasting syndromes: Current and future therapies. Semin Oncol 1998;25:1-3.

2. Balbameto G, Kotler Donald. Malnutrition in HIV infection. Gastroenterol Clin North Am 1997;26:393-415.

3. Kotler DP. Human immunodeficiency virus-related wasting: Malabsortion syndrome. Semin Oncol 1998;25:70-75.

4. Strawford A, Hellerstein M. The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. Semin Oncol 1998;S6:76-81.

5. Mulligan K, Bloch A. Energy expenditure and protein metabolismo in human immunodeficiency virus and cancer cachexia. Semin Oncol 1998;25:89-91.

6. Mulligan K, Schanbelan M. Wasting. The AIDS knowledge base P.T. Cohon, M.A. Sande, P.A. Voldering. University of California San Francisco 1999.

7. Macallan DC, Noble C. Energy expenditure and wasting in human immunodeficiency virus infection. NEJM 1995:333.

8. Grunfeld C. What causes wasting in ADIS? NEJM 1995; 333:123-126.

9. Sherer R. Current antiretroviral therapy and its impact on human immunodeficiency virus - Related wasting. Semin Oncol 1998;25:92-97.

10. Reyes-Terán G. Effects of thalidomide on HIV - associated wasting syndrome: a randomized, double blind, placebo controlled clinical trial. AIDS 1996;10:1501-1507.

11. Corcoran C, Grinspon S. Treatments for wasting in patients with the Acquired Immunodeficiency Syndrome. AIDS 1999:1740-175.

12. Schambelan M, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Ann Inter Med 1996;125:873-882.

13. Koch J. The role of body composition measurements in wasting syndrome. Semin Oncol 1998;25:12-19.

14. Muurahainen N, Mulligan K. Clinical trial update in human immunodeficiency virus wasting.

15. Evans WS, Roubenff R, Shevitz A. Exercise and the treatment of wasting: Aging and human immunodeficiency virus infection. Semin Oncol 1998;25:112-122.